Herbs (Global Traditional) · European
Vervain (Verbena officinalis) (Verbena officinalis)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Vervain (Verbena officinalis) is a European herb containing iridoid compounds verbenalin and hastatoside that may influence GABAergic pathways for sleep support. The plant also provides phenolic compounds like verbascoside with potential antioxidant activity.
Vervain (Verbena officinalis) is a perennial herb native to Europe from the Verbenaceae family, featuring slender stems, small lavender flowers, and lance-shaped leaves. The aerial parts are harvested at full bloom and extracted using solvents like methanol, ethanol, or water, with the dried herb containing high levels of iridoid glycosides, phenylpropanoid glycosides, and phenolic acids.
No human clinical trials, randomized controlled trials, or meta-analyses for Verbena officinalis were found in the available research. The evidence base consists entirely of chemical composition analyses, in vitro antioxidant assays, and animal/cell culture studies examining anti-inflammatory effects.
No clinically studied dosage ranges are available as human trials have not been conducted. Chemical analyses show standardized extracts may contain verbenalin (up to 6196 mg/100g dry weight), verbascoside (up to 2264 mg/100g), and hastatoside (up to 582 mg/100g). Consult a healthcare provider before starting any new supplement.
Vervain (Verbena officinalis) is consumed primarily as a herbal infusion rather than a food, so macronutrient contribution is negligible. Key bioactive compounds include: **Iridoid glycosides** – verbenalin (0.15–0.5% of dried herb) and hastatoside (0.1–0.3%), which are considered the primary pharmacologically active constituents and are linked to sedative and sleep-promoting effects. **Phenylpropanoid glycosides** – verbascoside (acteoside) at approximately 0.5–3.5% of dried herb, a potent antioxidant compound also found in olive leaves; isoverbascoside present in smaller amounts. **Flavonoids** – including apigenin, luteolin, and their glycosides (luteolin-7-O-diglucuronide), contributing to anti-inflammatory and mild anxiolytic potential; total flavonoid content approximately 0.2–0.8% of dried herb. **Phenolic acids** – caffeic acid, chlorogenic acid, and rosmarinic acid in trace to moderate amounts. **Triterpenoids** – ursolic acid and oleanolic acid detected in small quantities. **Volatile/essential oil** – present at very low concentration (<0.01%), containing citral, geraniol, and verbenone among minor terpene constituents. **Tannins** – approximately 3–5% of dried herb weight. **Minerals** – a typical herbal infusion (1–2 g dried herb per cup) provides only trace amounts of potassium, calcium, magnesium, and iron, nutritionally insignificant. **Vitamins** – no meaningful vitamin content in typical infusion doses. **Mucilage and fiber** – present in whole herb but not extracted significantly into tea. **Bioavailability notes**: Verbascoside has relatively low oral bioavailability (estimated <5–10%) due to extensive hydrolysis and first-pass metabolism; its metabolites (hydroxytyrosol, caffeic acid) may retain some bioactivity. Verbenalin and hastatoside are water-soluble iridoids reasonably extracted by hot water infusion, but their systemic bioavailability in humans has not been well characterized. Flavonoid glycosides require intestinal hydrolysis and are subject to glucuronidation, limiting free-form bioavailability. Standardized extracts typically target verbenalin content (≥1.5%) or verbascoside for quality assurance.
Vervain's iridoid compounds verbenalin and hastatoside may modulate GABAergic neurotransmission, potentially enhancing GABA receptor activity to promote relaxation and sleep. The phenolic compound verbascoside exhibits antioxidant activity by scavenging free radicals and reducing oxidative stress markers. Traditional anti-inflammatory effects may involve inhibition of pro-inflammatory cytokines, though specific pathways remain unclear.
Clinical evidence for vervain remains extremely limited, with most research confined to laboratory isolation studies of bioactive compounds. No randomized controlled trials have evaluated vervain's sleep-promoting effects in humans, despite traditional use for this purpose. In vitro studies demonstrate antioxidant activity of verbascoside extracts, but human bioavailability and therapeutic doses are unknown. Current evidence is insufficient to establish clinical efficacy for any health condition.
Vervain is generally considered safe for short-term use in healthy adults, though comprehensive safety data is lacking. No documented drug interactions exist, but theoretical concerns include potential additive effects with sedative medications due to possible GABAergic activity. Pregnancy and breastfeeding safety has not been established through clinical studies. Individuals with hormone-sensitive conditions should exercise caution, as some Verbena species may have estrogenic activity.
